SCHEMBL20764658

SCHEMBL20764658

CC(C)(C)OC(=O)N[C@@H](C(=O)O)c1cccc(C(F)(F)F)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 1/20 0.49
CTSK P43235 1/20 0.49
RXFP1 Q9HBX9 1/20 0.47
NPSR1 Q6W5P4 2/20 0.47
CES2 O00748 1/20 0.47
GABRB1 P18505 1/20 0.46
GABRB2 P47870 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.45
KDM4E B2RXH2 1/20 0.45
PPARG P37231 1/20 0.44
PPARA Q07869 1/20 0.44
ACP3 P15309 1/20 0.44
KLRK1 P26718 2/20 0.43
MICA Q29983 2/20 0.43
RAET1L Q5VY80 2/20 0.43
ATM Q13315 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP1A2 P05177 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL381877 1.00 CTSS (0.49) CTSSCTSKRXFP1NPSR1CES2
SCHEMBL30117107 1.00 CTSS (0.49) CTSSCTSKRXFP1NPSR1CES2
SCHEMBL13168021 1.00 CTSS (0.49) CTSSCTSKRXFP1NPSR1CES2
SCHEMBL8752678 0.89 NPSR1 (0.49) NPSR1CES2SMN1; SMN2KDM4EPPARG
SCHEMBL18305550 0.88 RXFP1 (0.46) CTSSCTSKRXFP1NPSR1CES2
SCHEMBL29072735 0.87 CTSS (0.50) CTSSCTSKRXFP1NPSR1CES2
SCHEMBL6917242 0.86 CTSS (0.49) CTSSCTSKRXFP1NPSR1CES2
SCHEMBL8235992 0.86 KLRK1 (0.59) CTSSCTSKRXFP1NPSR1KLRK1
SCHEMBL23886604 0.85 CTSS (0.50) CTSSCTSKNPSR1CES2GABRB1
SCHEMBL23886596 0.85 CTSS (0.50) CTSSCTSKNPSR1CES2GABRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118955391-A Substituted N- (2-oxo ethyl) benzamide derivative and preparation method and application thereof 中国医学科学院医药生物技术研究所 2024-11-15 CN disclosed
CN-111372928-B Benzimidazole derivatives as potassium channel inhibitors 阿塞西翁制药公司 2023-05-16 CN disclosed
US-11168074-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2021-11-09 US disclosed
US-11168074-B2 Potassium channel inhibitors ACESION PHARMA APS (DK) 2021-11-09 US disclosed
EP-3672953-B1 BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2021-07-28 EP disclosed
US-20200255409-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-08-13 US disclosed
US-20200255409-A1 NOVEL POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2020-08-13 US disclosed
CN-111372928-A Benzimidazole derivatives as potassium channel inhibitors 阿塞西翁制药公司 2020-07-03 CN disclosed
EP-3672953-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS Acesion Pharma ApS (DK) 2020-07-01 EP disclosed
WO-2019038315-A1 BENZIMIDAZOLE DERIVATIVES USEFUL AS POTASSIUM CHANNEL INHIBITORS ACESION PHARMA APS (DK) 2019-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255409-A1 NOVEL POTASSIUM CHANNEL INHIBITORS KCNN1, KCNN2, KCNJ2 CTSS 4114/4885CTSK 2205/4885RXFP1 1162/4885
US-11168074-B2 Potassium channel inhibitors KCNN2, KCNJ2, KCNN1 CTSS 4010/4885CTSK 1911/4885RXFP1 1512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.